Should Clinics Prescribe Medicinal Cannabis that They Also Supply? We Asked 5 Experts

Why It Matters

The issue threatens the integrity of medical decision‑making and could expose patients to unsafe, untested products, prompting urgent regulatory action.

Key Takeaways

• Prescription rates for medicinal cannabis have surged in Australia
• Vertical integration creates conflict of interest for prescribers
• Unapproved products dominate market, raising safety concerns
• Experts unanimously oppose clinics dispensing their own prescriptions
• Regulators consider stricter rules to prevent profit-driven prescribing

Pulse Analysis

The rapid rise of medicinal cannabis use in Australia reflects a broader shift toward telehealth and streamlined supply chains. Online consultations promise speed and convenience, yet the majority of prescriptions involve products that lack formal approval, leaving clinicians and patients navigating an uncertain safety landscape. This market dynamic has attracted both legitimate providers and opportunistic operators, inflating demand while obscuring evidence of efficacy.

At the heart of the controversy is vertical integration, where the same entity that writes a prescription also profits from its sale. Such arrangements create a clear incentive to favor higher‑margin products, potentially sidelining clinical judgment and locking patients into specific brands or pharmacies. The five experts consulted—spanning pharmacovigilance, health policy, and clinical practice—concurred that this model compromises patient autonomy and could erode trust in the healthcare system.

Regulators, led by the Therapeutic Goods Administration, are responding with a consultation aimed at tightening controls on unapproved cannabis products and separating prescribing from dispensing functions. Proposed measures include stricter conflict‑of‑interest disclosures, independent supply chains, and heightened post‑market surveillance. For clinics, compliance will require re‑engineering business models, while manufacturers may need to pivot toward transparent partnerships. Ultimately, the policy shift seeks to balance patient access with rigorous safety standards, ensuring that medicinal cannabis delivers therapeutic benefit without undue commercial influence.